Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
An update from Noxopharm Ltd. ( (AU:NOX) ) is now available.
Noxopharm Limited has secured its first US patent for the Sofra™ technology platform, which is designed to harness immune-modulatory oligonucleotides for cancer treatment. This patent protects the structure of Noxopharm’s assets, ensuring the commercial value of their ongoing cancer research. The Sofra platform, developed in collaboration with the Hudson Institute of Medical Research, shows potential for versatile applications in mitigating inflammation and weaponizing the immune system against cancer. This milestone positions Noxopharm favorably in the growing immuno-oncology market, projected to expand significantly in the coming years.
More about Noxopharm Ltd.
Noxopharm Limited is a clinical-stage Australian biotech company focused on discovering and developing novel treatments for cancer and inflammation. It utilizes its proprietary technology platforms, Sofra™ and Chroma™, to create new drugs targeting inflammation, autoimmunity, mRNA drug enhancement, and oncology. The company collaborates with leading researchers to enhance its drug development pipeline.
Average Trading Volume: 226,833
Technical Sentiment Signal: Hold
Current Market Cap: A$27.18M
For detailed information about NOX stock, go to TipRanks’ Stock Analysis page.